In the BioHarmony Drug Report Database

"Preview" Icon

Nonacog beta pegol

Refixia (nonacog beta pegol) is a protein pharmaceutical. Nonacog beta pegol was first approved as Refixia on 2017-06-02. It has been approved in Europe to treat hemophilia b.

 

Trade Name

 

Refixia
 

Common Name

 

nonacog beta pegol
 

ChEMBL ID

 

CHEMBL2108348
 

Indication

 

hemophilia b
 

Drug Class

 

Pegylated compounds

Image (chem structure or protein)

Nonacog beta pegol structure rendering